Viking Therapeutics, Inc.
VKTX
$35.63
$0.160.45%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -345.16% | -264.02% | -194.66% | -66.80% | -43.94% |
| Total Depreciation and Amortization | -14.55% | 31.03% | 49.33% | 50.00% | 48.65% |
| Total Amortization of Deferred Charges | -100.00% | -66.67% | 33.33% | -14.29% | -7.69% |
| Total Other Non-Cash Items | 313.06% | 36.06% | 573.51% | 59.12% | 18.59% |
| Change in Net Operating Assets | 2,566.08% | -737.50% | 189.90% | -194.43% | -55.16% |
| Cash from Operations | -173.53% | -328.03% | -65.05% | -753.13% | -76.76% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 1,048.42% | 517.83% | 133.72% | 113.76% | -81.57% |
| Cash from Investing | 1,048.42% | 517.83% | 133.72% | 113.76% | -81.57% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 7,410.30% | -80.97% | -82.55% | -99.95% | 431.91% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 7,410.30% | -80.97% | -82.55% | -99.94% | 431.91% |
| Foreign Exchange rate Adjustments | 112.16% | 79.31% | -500.00% | 102.08% | -248.00% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 376.43% | 933.83% | 97.32% | -91.96% | -229.13% |